Argan

As of April 30, 2026, Argan held about 355.8 million dollars in cash and 617.7 million dollars in investments, had no debt, and maintained credit facilities and letter‑of‑credit capacity. FY2026 cash from operations was about 414.7 million dollars, aided by early‑phase contract liabilities; capex needs are modest.

This balance sheet supports bonding, absorbs working‑capital swings, and enables patient project selection.